Drug-Induced Vasculitis and Choroiditis after Brolucizumab

Area of Science:

• Ophthalmology
• Retinal Diseases
• Immunology

Background:

• Intravitreal brolucizumab is a novel treatment for retinal diseases.
• Adverse ocular events have been reported with brolucizumab therapy.
• Immune-mediated inflammatory conditions can affect the retina and choroid.

Purpose of the Study:

• To report two cases of retinal vasculopathy and choroiditis after intravitreal brolucizumab.
• To describe the clinical presentation, severity, and outcome of these cases.
• To emphasize the importance of monitoring and management strategies.

Main Methods:

• Case report of two patients treated with intravitreal brolucizumab.
• Clinical examination, imaging (e.g., OCT, FA), and laboratory tests.
• Review of relevant literature on brolucizumab-associated retinopathy.

Main Results:

• Both patients developed immune-mediated retinal vasculopathy and choroiditis.
• The condition was characterized by significant inflammation and vision impairment.
• The observed complications were severe and irreversible in both cases.

Conclusions:

• Intravitreal brolucizumab can induce serious immune-mediated ocular inflammation.
• Vigilant monitoring for signs of retinal vasculopathy and choroiditis is essential.
• Multidisciplinary management is recommended to mitigate vision-threatening complications.